Evidation Health and Eli Lilly Study Uses Apple Devices and Apps to Predict Cognitive Impairment

The results of the trial set the groundwork for future research that may be able to help identify people with neurodegenerative conditions.

Aug 11, 2019 | By Kevin Truong | MedCity News

The growing ubiquity of powerful sensor technology in consumer devices have led to the development of tools meant to predict potential health risks like heart attacks and epileptic seizures. Increasingly, these devices may also be of use in the case of neurodegenerative conditions.

Early results from a study conducted by Evidation Health, Eli Lilly and Apple have shown the ability to detect cognitive decline and mild Alzheimer’s disease using a combination of Apple wearables, mobile devices, digital apps and sleep sensors. Devices used included the iPhone, Apple Watch, iPad and the Beddit sleep monitoring device.

The early data also showed the ability to differentiate between people with mild cognitive impairment and mild Alzheimer’s disease.

The study, which included 113 individuals between the ages of 60 and 75, examined data acquired from a range of different sources including passively collected sensor data, surveys about mood and energy and assessments through a digital app developed by the researchers which had participants perform reading, typing and psychomotor tasks.

Through this data, researchers were able to link certain behaviors or markers that were indicative of cognitive impairment including typing speed, when individuals took their first daily step and the total number of messages received by participants.

The researchers also identified poor survey compliance and a reliance on “helper apps” like Siri and the Clock app as signifiers of cognitive decline.

“Over the past few years, we’ve seen how data and insights derived from wearables and mobile consumer devices have enabled people living with health conditions, along with their clinicians, to better monitor their health,” Evidation Health data scientist Nikki Marinsek in a statement.

“We know that insights from smart devices and digital applications can lead to improved health outcomes, but we don’t yet know how those resources can be used to identify and accelerate diagnoses. The results of the trial set the groundwork for future research that may be able to help identify people with neurodegenerative conditions earlier than ever before.”

Ultimately, the researchers hope to be able to use the learnings gleaned from the research to develop early screening tools for those at high risk of cognitive decline  or detect dementia and Alzheimer’s disease earlier using common devices.

TRNDS 2019

University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642

Date: Friday, September 13
Time: 7:30 am – 4:00pm

TRNDS News

Sign-up for TRNDS updates and rare disease news

  • New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
    READ MORE
  • Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
    READ MORE
  • NIH launches 5-year, $10 million study on acute flaccid myelitis
    READ MORE
  • Study refines ALS risk among first-degree relatives of patients with disease
    READ MORE
  • NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
    READ MORE
  • Speeding Up Drug Discovery for Brain Diseases
    READ MORE
  • NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
    READ MORE
  • Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
    READ MORE
  • Jsyne Gershkowitz, Amicus Therapeutics, TRNDS 2019
    (Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
    READ MORE
  • PJ Brooks, NCATS, NIH, TRNDS
    Meet TRNDS 2019 Speaker PJ Brooks
    READ MORE
  • Rare Pediatric Disease PRVs: FDA Updates Guidance
    READ MORE
  • Batten Disease Study
    Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
    READ MORE
  • C-Path and NORD Collaborate to Launch Rare Disease Data Platform
    READ MORE
  • TRNDS 2019 speaker Tauna Batiste, BDSRA
    Meet TRNDS Speaker Tauna Batiste
    READ MORE
  • HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
    READ MORE
  • Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
    READ MORE
  • 'Dr. Google' Helps Some Patients Diagnose a Rare Disease
    READ MORE
  • Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
    READ MORE
  • Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
    READ MORE
  • Netflix's Medical Investigation Docuseries 'Diagnosis'
    READ MORE
  • NIH All of Us Project Tops 270,000 Sign-ups
    READ MORE
  • FDA Cancer Office Taps Syapse for Real-world Evidence Development
    READ MORE

Latest Tweets

TRNDS Speakers

Room Block

Hilton Garden Inn
Rochester/University
Medical Center

30 Celebration Drive
Rochester, NY 14620

Phone: 585-424-4404

TRNDS Rate: $149/night